According to the study an interdisciplinary approach to antimicrobial stewardship involving the comprehensive blood culture; identification testing decreased broad spectrum antibiotic use. This involving raise reimbursements for novel antibiotics; a meaningful step in confronting the threat of infections resistant to older medicines. But the collaboration with the antimicrobial stewardship team, implementing a new protocol to treat sepsis patients.
Rapid BCID polymerase chain reaction tests were administering to identify the bacteria making the patient sick; and pharmacists made recommendations on how to manage or readjust the previously prescribed antibiotic regimen. Multidrug resistant organisms cause a significant proportion of serious healthcare associated infections (HAIs) and are more difficult to treat because there are fewer and, in some cases, no antibiotics that will cure the infection.
Compensating for new antibiotics
Responsive to concerns raised by the Infectious Diseases Society of America and other organizations, and increasing both the severity level designation for antimicrobial resistance in Medicare coding and the payment levels for new technologies, the rule aims to allow the use of newer and higher-priced antibiotics when necessary.
While these changes can open access to effective medicines to treat infections resistant to first-line drugs, how effective the rule will be in practice on its own remains uncertain. While hospital antibiotic stewardship programs have been demonstrated to improve patient outcomes; reduce health care costs and reduce inappropriate antibiotic use that drives the development of antibiotic resistance, the rule does not address needs to support and incentivize those programs.
Growth of resistant bacteria
Reducing the use of broad spectrum antibiotics is essential in slowing the growth of resistant bacteria. Through rapid blood culture identification tests, we are able to tailor patients’ antibiotic regimen and ultimately improve their care. While the new rule may improve access to novel antibiotics; and remove one of many disincentives to developing them; the policy on its own also is unlikely to lead to sufficient returns on investments in new antibiotic research and development.
This scenario illustrates the success that antimicrobial stewardship programs can achieve when healthcare providers, pharmacists, and infection preventionists work together; Additional support and investments on a federal level that reflects the value of new antibiotics to individual and public health; and to the practice of modern medicine remain essential to combating antibiotic resistance.